187 research outputs found
Il Bilancio d'esercizio delle societĂ di calcio professionistiche. Il caso U.S. CittĂ di Pontedera.
Da uno sguardo sull'evoluzione storico-giuridica del sistema calcio, all'analisi del bilancio delle società di calcio professionistiche passando attraverso la disciplina normativa a cui è sottoposta la redazione del principale strumento di comunicazione economico-finanziaria.
Il lavoro svolto si propone di analizzare il bilancio delle societĂ di calcio, evidenziandone le voci tipiche, con particolare attenzione alle societĂ di provincia, nella fattispecie l'U.S. CittĂ di Pontedera.
Nell'ultima parte del lavoro si è cercato di valutare le scelte gestionali che hanno consentito alla società U.S. Città di Pontedera di presentare un bilancio "in salute", condizione confermata anche dalla comparazione con bilanci di altre società similari militanti nella stessa categoria
Monocytes and CD4+ T cells contribution to the under-expression of NR4A2 and TNFAIP3 genes in patients with multiple sclerosis
Rituximab suppresses disease activity after natalizumab withdrawal: an exploratory study
Background Natalizumab is highly effective in reducing multiple sclerosis disease activity; however it carries a risk of progressive multifocal leukoencephalopathy, that represents the main reason of drug discontinuation. After natalizumab withdrawal, reactivation of disease is soon observed and, until now, it is not known which treatment strategy should be followed after natalizumab discontinuation. Aim of this study is to evaluate rituximab efficacy in controlling disease activity after natalizumab withdrawal
Successful pregnancy and disease outcomes in a NMOSD patient treated with tocilizumab
Abstract Background Neuromyelitis Optica Spectrum Disorder (NMOSD) is an autoimmune relapsing disease involving the central nervous system with predominant inflammatory attack of optic nerves, spinal cord and area postrema, often leading to severe disability. Women with NMOSD typically experience adverse pregnancy outcomes and high relapse rates during pregnancy and the postpartum period. Case report Herein we present a case of pregnancy in a young NMOSD woman treated with tocilizumab. The course of her pregnancy was clinically unremarkable and treatment whit Tocilizumab was well tolerated. Conclusions This case raises the possibility that the modulation of immune system by inhibitors of the IL-6 pathway could a promising therapeutic option for pregnancy in NMOSD patient
Serum neurofilament light chain levels in healthy individuals: A proposal of cut-off values for use in multiple sclerosis clinical practice
Neutralizing antibodies against IFNâβ in multiple sclerosis: antagonization of IFNâβ mediated suppression of MMPs
Neutralizing antibodies (NAb) against interferonâβ (IFNâβ) develop in about a third of treated multiple sclerosis patients and are believed to reduce therapeutic efficacy of IFNâβ on clinical and MRI measures. The expression of the interferon acuteâresponse protein, myxovirus resistance protein A (MxA) is a sensitive measure of the biological activity of therapeutically applied IFNâβ and of its reduced bioavailability due to NAb. However, MxA may not be operative in the pathogenesis of multiple sclerosis or the therapeutic effect of IFNâβ. Instead, matrix metalloproteinases (MMPs) are increased in brain tissue, CSF and blood circulation of multiple sclerosis patients and function as effector molecules in several steps of multiple sclerosis pathogenesis. One of the molecular mechanisms by which IFNâβ exerts its beneficial effect in multiple sclerosis is reduction of MMPâ9 expression and increase of its endogenous tissue inhibitor, TIMPâ1. Quantitative PCR measurements of MMPâ2 and MMPâ9, TIMPâ1 and TIMPâ2, and MxA were performed in peripheral mononuclear cells from clinically stable multiple sclerosis patients with relapsing remitting disease course after shortâterm and longâterm treatment with IFNâβ. IFNâβ therapy downâregulated the expression of MMPâ9 and abolished that of MMPâ2 in longâterm, but not shortâterm treated multiple sclerosis, while levels of MxA were increased in both instances. The presence of NAb reversed these effects, i.e. led to reduced MxA and increased MMPâ2/MMPâ9 expression levels compared with NAb- patients. In contrast, expression of TIMPs in peripheral blood mononuclear cells remained unaffected by IFNâβ therapy and the presence of NAb. While MxA is able to detect the biological action and reduced bioavailability of IFNâβ on the basis of single injections, only MMPâ9 shows quantitative correlation with the NAb titre. Together with evidence that an imbalance between MMP and TIMP expression is a crucial pathogenetic feature in multiple sclerosis, these findings support the concept of a significant role of NAb in reducing the therapeutic efficacy of IFNâ
The use of the 25 Sprotte needle markedly reduces post-dural puncture headache in routine neurological practice
Prevalence and Significant Determinants of Post-traumatic Stress Disorder in a Large Sample of Patients with Multiple Sclerosis
- âŚ